Jiangsu Qyuns Therapeutics, a Taizhou company that develops monoclonal antibody drugs for autoimmune diseases, raised $20 million in a Series B financing led by Hongtai Capital. Founded in 2015, Qyuns is developing six candidates, most of them interleukin antibodies. It has two biosimilar drugs in China clinical trials, including a biosimilar to tocilizumab, a Chugai drug marketed as Actemra for various rheumatoid arthritis conditions. Triwise Capital, a Shenzhen VC investor, also participated in the B round. Source: China Biotoday
